Latest News and Press Releases

NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in...

NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A...

NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S....

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of...

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will...

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President,...

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will...

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaidZymeworks to retain...

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46th Annual Health Care Conference on March 3,...

Portfolio Receipts of $874 million in Q4 2025 and $3,254 million for FY 2025 Portfolio Receipts growth of 18% in Q4 2025 and 16% for FY 2025Net cash provided by operating activities of $827 million in...